Skip to Main Content

Paper Details

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
Nat Commun
39
2021
B., COVA1-18, COVA1-18 neutralizing antibody, SARS, SARS-CoV, SARS-CoV-2, Severe Acute Respiratory Syndrome, Syrian hamsters, cynomolgus macaques, hACE2, lung lesions, lymphopenia, mice, patients
Author NameAffiliation
Natalia A KuzminaUniversity of Texas Medical Branch at Galveston
Natalia A KuzminaGalveston National Laboratory
Raveen RathnasingheIcahn School of Medicine at Mount Sinai
Raveen RathnasingheIcahn School of Medicine at Mount Sinai
David C MontefioriDuke Human Vaccine Institute & Department of Surgery
Ian A WilsonThe Scripps Research Institute
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreIcahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Adolfo Garc??a-SastreGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Michael SchotsaertIcahn School of Medicine at Mount Sinai
Michael SchotsaertGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Lynda CoughlanIcahn School of Medicine at Mount Sinai
Lynda CoughlanUniversity of Maryland School of Medicine, Department of Microbiology and Immunology and Center for Vaccine Development and Global Health (CVD)
  • 1 - 14

Datasets

Release 1.2